Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Belgium
/
Healthcare
/
Nyxoah
NYXH
Nyxoah
Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
17 Aug 25
Updated
28 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€6.00
10.2% undervalued
intrinsic discount
28 Aug
€5.39
1Y
-27.2%
7D
0.6%
Loading
1Y
-27.2%
7D
0.6%
Author's Valuation
€6.0
10.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€6.0
10.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-176m
89m
2017
2019
2021
2023
2025
2027
2028
Revenue €89.1m
Earnings €3.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
52.85%
Medical Equipment revenue growth rate
0.45%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.00%
Calculation
€3.60m
Earnings '28
x
98.43x
PE Ratio '28
=
€354.82m
Market Cap '28
€354.82m
Market Cap '28
/
48.29m
No. shares '28
=
€7.35
Share Price '28
€7.35
Share Price '28
Discounted to 2025 @ 6.98% p.a.
=
€6.00
Fair Value '25
